NCT05835778Completed
Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Specific Use-results Study of IMFINZI Intravenous Infusion 120 mg,500mg in Patients With Curatively Unresectable Biliary Tract Cancer
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 236 (actual)
- First submitted
- 6 Apr 2023
- Start date
- 6 Jun 2023
- Primary completion date
- 21 Nov 2025
- Lead sponsor
- AstraZeneca
- NCT number
- NCT05835778
What you commit to
- Study type: Observational
- Participants enrolled: 236
- From 6 Jun 2023 to the primary completion date, 21 Nov 2025
- 24 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Patients with curatively unresectable biliary tract cancer who receive IMFINZI for the first time in combination with gemcitabine hydrochloride and cisplatin.
Sex: All · Does not accept healthy volunteers
Sites (24)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.